A new stem cell-based treatment helped most trial participants with severe type 1 diabetes stop insulin use, offering hope ...

Vertex Pharmaceuticals has received a “Moderate Buy” consensus from 29 brokerages, with most analysts either holding or ...

The American Diabetes Association's McCormick Place event was also a bit of a coming out party for North Chicago-based Abbott ...

Analysts remain bullish on Vertex Pharmaceuticals as HC Wainwright reaffirmed its buy rating with a $550 price target.

Researchers at Vertex Pharmaceuticals in Boston say a single infusion of stem cell-based treatment could be a permanent ...

This was the stock's second consecutive day of gains.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best biotech stocks to invest in now. On June 20, Vertex ...

A study may have found a cure for type 1 diabetes. Here, experts explain how the treatment, zimislecel, works and what it ...

TUESDAY, June 24, 2025 (HealthDay News) — A single infusion of a new stem cell-based treatment may have helped 10 out of 12 ...

CHICAGO -- Mifepristone (Korlym) reduced HbA1c levels in patients with inadequately controlled type 2 diabetes and ...

"This edition of the Healthcare Enforcement column discusses two judicial decisions from recent months relating to the ...

While BMO Capital Markets said that zimislecel is “highly encouraging” for type 1 diabetes, questions regarding its target ...